{"organizations": [], "uuid": "b708842ac4bcd1f474db74650683944e8b5d1af5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sanbio-and-teijin-to-terminate-lic/brief-sanbio-and-teijin-to-terminate-licensing-agreement-regarding-sb623-for-stroke-treatment-idUSL4N1Q43QZ", "country": "US", "domain_rank": 408, "title": "BRIEF-SanBio and Teijin to terminate licensing agreement regarding SB623 for stroke treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.025, "site_type": "news", "published": "2018-02-14T17:16:00.000+02:00", "replies_count": 0, "uuid": "b708842ac4bcd1f474db74650683944e8b5d1af5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sanbio-and-teijin-to-terminate-lic/brief-sanbio-and-teijin-to-terminate-licensing-agreement-regarding-sb623-for-stroke-treatment-idUSL4N1Q43QZ", "ord_in_thread": 0, "title": "BRIEF-SanBio and Teijin to terminate licensing agreement regarding SB623 for stroke treatment", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "teijin", "sentiment": "negative"}, {"name": "teijin limited", "sentiment": "negative"}, {"name": "reuters) - sanbio co ltd", "sentiment": "neutral"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - SanBio Co Ltd\n* Says co and Teijin Limited would terminate the exclusive licensing agreement signed in 2009, regarding the development and marketing of SB623 for stroke treatment in Japan\nSource text in Japanese: goo.gl/1xt25t\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://goo.gl/1xt25t", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T17:16:00.000+02:00", "crawled": "2018-02-15T20:28:06.013+02:00", "highlightTitle": ""}